NCT01723800View on ClinicalTrials.gov

PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Recurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

PI3K inhibitor BKM120

Given PO

DRUG

pemetrexed disodium

Given IV

DRUG

carboplatin

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

PROCEDURE

quality-of-life assessment

Ancillary studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01723800 - PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter